Lorbriqua (Lorlatinib) Tablet

Description

Description

This page contains brief details about the drug lorlatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Lorlatinib is a targeted cancer medication that was approved for its medical use on 2nd November 2018.

Mechanism of Action of Lorlatinib

Lorlatinib Tablet is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a kinase inhibitor and comes under the class of ALK and ROS-1 inhibitor. Anaplastic Lymphoma Kinase and ROS proto-oncogene are the two genes that promote cellular proliferation and tumour growth in non-small cell lung cancer by undergoing mutation. It works by inhibiting the cell signaling of these genes, ultimately inhibiting tumour growth.

Uses of Lorlatinib

Lorlatinib Tablet has been developed to treat adults with Non-small cell lung cancer (NSCLC) that resulted due to mutation in Anaplastic Lymphoma Kinase and ROS-1 genes and has spread to other parts of the body.

Lorlatinib Dosage available

Your doctor will decide the dose and duration of Lorlatinib based on the disease condition and other factors. Take the tablet at the same time everyday, with or without food. Do not chew, crush, or break the tablet. Swallow the whole tablet with water. If you forgot to take the tablet, simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.